A collaborative research project funded by the European Commission.
MYASTERIX is a 5-year collaborative research project started in October 2013 and supported by the European Commission under the Health priority of 7th Framework programme. The science of the project is coordinated by CuraVac, a Belgian SME specialized in therapeutic vaccines for autoimmune diseases.
Around CuraVac, MYASTERIX consortium brings together 5 complementary partners: a small and medium enterprise from Austria named piCHEM that has specific expertise in peptide vaccine synthesis/conjugation and GMP accreditation to manufacture vaccines; the Leiden University Medical Center,a referral site for myasthenia gravis in the Netherlands; the Antwerp University Hospital, an academic center renowned for leading clinical and customer friendly patient care; Aepodia, a Belgian SME specialising in conducting clinical trials as well as Inserm Transfert, a technology transfer & management company based in France.
To download the project brochure, please click here.
Watch a short video on the vaccine mechanism:
Version with text: https://www.youtube.com/watch?v=ACVI3zkq7sM
Version without text: https://www.youtube.com/watch?v=aoEMaOQxVFE
Photo: Myasterix Consortium, annual meeting September 2016